Comprehensive serum cytokine analysis identi fi es IL-1RA and soluble IL-2R α as predictors of event-free survival in T-cell lymphoma

malignancies are heterogeneous in their clinical presentation and pathology, have a poor prognosis. New biomarkers are needed to predict prognosis and to provide insights into signal pathways used by these cells. evaluate pretreatment serum cytokines in patients T-cell neoplasms 30 in from 68 and 14 normal cytokines with of event-free survival (EFS) and overall survival (OS). Our demonstrated signi fi cantly elevated levels (versus controls) of seven cytokines — epidermal growth factor (EGF), IL-6, IL-12, interferon gamma-induced protein (IP)-10, soluble interleukin (sIL)-2R α , monokine induced by gamma interferon (MIG), and IL-1RA — in all T-cell neoplasms ( P < 0.05). In the angioimmunoblastic subset, all seven cytokines except IP-10 and in the peripheral T-cell lymphoma (TCL)-not otherwise speci fi ed subset, only IP-10, sIL-2R α , MIG, and IL-8 were statistically elevated compared with control. Of these, elevated cytokines all but EGF were predictive of an inferior EFS; IL-1RA, sIL-2R α and MIG predicted an inferior OS. In a multivariate analysis, sIL-2R α [hazard ratio (HR) = 3.95; 95% con fi dence interval (CI) 1.61 – 8.38] and IL-1RA (HR = 3.28; 95% CI 1.47 – 7.29) remained independent predictors of inferior EFS. TCL cell lines secreted high levels of sIL-2R α and the IL-2R α surface receptor. and sIL-2R α as biomarkers in future trials. Inhibition of these cytokines may also be of therapeutic bene fi t. received only radiation therapy; 16% (11/68) were observed; and in 2 the regimen was not available. otherwise speci fi ed; AITLTCL, angioimmunoblastic T-cell lymphoma. Background: To establish the role of antiemetic therapy with neurokinin-1 (NK 1 ) receptor antagonists (RAs) in nonan-thracycline and cyclophosphamide (AC)-based moderately emetogenic chemotherapy (MEC) regimens, this study evaluated single-dose intravenous (i.v.) fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with non-AC MEC.